Major Alzheimer's group says some blood tests may be used in place of brain scans for diagnosis

The Alzheimer's Association has issued its first clinical guidelines endorsing the use of high-accuracy blood tests for diagnosing cognitive impairment, potentially replacing more invasive PET scans and CSF tests for patients under specialist care. This development, spurred by recent Alzheimer's drug approvals, is poised to accelerate diagnoses, especially in rural areas, thereby increasing patient access to new therapies and creating significant market opportunities for diagnostic test developers and pharmaceutical companies like Eisai, Biogen, and Eli Lilly, though PET scans remain vital for monitoring treatment efficacy.

Analysis

The Alzheimer's Association has issued its first clinical guidelines for blood-based biomarkers, a significant development poised to accelerate the diagnosis and treatment of Alzheimer's disease. The guidelines endorse the use of high-accuracy blood tests (over 90% sensitivity and specificity) as an alternative to more invasive and costly PET scans or cerebrospinal fluid tests for patients already under specialist care for cognitive impairment. This move is a direct catalyst for broader adoption of new amyloid-targeting therapies from Eisai, Biogen, and Eli Lilly, as it addresses a key bottleneck in the patient journey: accessible and scalable diagnosis. However, the guidelines are cautious, noting significant variability in the accuracy of commercially available tests and clarifying their current role is for diagnosis, not for monitoring treatment efficacy. For monitoring amyloid plaque reduction during therapy, PET scans remain the recommended standard, ensuring continued relevance for imaging providers. The framework also creates a two-tiered system, allowing tests with lower specificity (over 75%) to be used for triage, which could expand the funnel of potential patients but requires confirmatory testing. Eli Lilly's proactive telehealth partnership to streamline diagnosis and prescription highlights a strategic move to capitalize on these new diagnostic pathways, potentially setting a competitive benchmark.

Key Decisions for Investors

• The new guidelines represent a significant long-term tailwind for pharmaceutical firms with approved Alzheimer's therapies like Eli Lilly, Biogen, and Eisai, as simplified diagnostics will likely accelerate patient uptake and revenue.
• Investors should closely monitor the diagnostics sector for companies developing blood tests that meet the Alzheimer's Association's high-accuracy thresholds, as these firms are now positioned to become critical players in the treatment ecosystem.
• While blood tests will dominate initial diagnosis, the continued necessity of PET scans for treatment monitoring suggests that medical imaging companies will retain a crucial and potentially growing role as more patients begin therapy.
• Consider Eli Lilly's proactive strategy in integrating diagnostics via telehealth as a potential competitive advantage in patient acquisition compared to its peers.